Pharmaceutical Commerce
CONTINUE TO SITE >

OR WAIT 15 SECS

Pharmaceutical Commerce - July/August 2017

Pharmaceutical traceability stumbles ahead

July 17, 2017

FDA’s delay will not alter industry goals

Managing employee training at the enterprise level

July 17, 2017

The case for a single enterprise-wide learning management system

Blockchain: the technology to make DSCSA work after 2023?

July 17, 2017

Industry experts are grappling with the eventual requirement to provide accurate supply-chain traceability

Besse Medical acquires Podis

July 17, 2017

Managing physician office drug inventory

Woodfield Distribution offers 3PL-based DSCSA compliance services

July 17, 2017

More serialization options, especially for low-volume pharma manufacturers struggling with the November 2017 deadline

DHL opens a cold-chain center of excellence in Ireland

July 17, 2017

40,000-sq. ft. facility is near Dublin Airport

Construction starts on a Pfizer biopharma plant near St. Louis

July 17, 2017

Completion scheduled for 2019

Looking ahead in life sciences and healthcare logistics

July 17, 2017

New DHL report sees transformational trends

Pharma’s cold chain is going below zero

July 17, 2017

Cellular and genetic therapies drive a ‘new paradigm’ for logistics

Digital opinion leaders (DOLs) and their role in pharma markets

July 17, 2017

Like traditional thinking about key opinion leaders (KOLs) in healthcare, consider the DOL as part of a marketing campaign

Walgreens-Rite Aid merger falls away, replaced by sale of some stores

June 29, 2017

$325-million cancellation fee to be paid to Rite Aid

URAC plans a specialty-pharmacy workshop in conjunction with the NASP annual meeting

June 28, 2017

Specialty pharmacy accreditation attracts growing number of pharmacies

HDA honors 2017 DIANA winners, Lifetime Achievement Nexus winner

June 28, 2017

Lifetime Achievement Award goes to Michael McBride, Upsher-Smith Labs

Woodfield Distribution offers 3PL-based DSCSA compliance services

June 16, 2017

More serialization options, especially for low-volume pharma manufacturers struggling with the November 2017 deadline